No Data
Company Research Report: Tsubota Laboratory, Inc. (4890)
Tsubota Lab --- Business Plan and Growth Potential
On the 27th, Tsubota Lab <4890> announced matters regarding its business plan and growth potential. Regarding the performance forecast for the fiscal year ending March 2026, revenue is expected to reach 1.4 billion yen, an increase of 3.2% compared to the previous period, updating the record high. This is primarily due to an increase in upfront payments from pipeline licensing agreements centered on pharmaceuticals, with the revenue composition expected to be 84% pharmaceuticals, 14% Medical Devices, and 2% healthcare products. On the other hand, proactive preliminary investments for future growth are being pursued.
Tsubota Laboratory: Extraordinary Report
Tsubota Laboratory: Confirmation
Tsubota Laboratory: Financial Report - 13th Term (2024/04/01 - 2025/03/31)
Pita Lab --- The expansion of the pipeline in the area of eye diseases and the conclusion of licensing agreements are progressing smoothly.
Tsubota Lab <4890> is a bio venture originating from Keio University that is developing Medical Devices and pharmaceuticals using violet light, which is expected to have effects on the suppression of myopia progression and brain activation. It went public on the Tokyo Stock Exchange Growth Market in June 2022.